Showing results (161-170 of 187) with videos related to
Sort By:
Pageof 19
American Journal of Clinical Dermatology|May 3, 2022
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic DermatitisLisa A Beck, Mette Deleuran, Robert Bissonnette, et al.Paediatric Drugs|August 31, 2021
Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical TrialAmy S Paller, Andreas Wollenberg, Elaine Siegfried, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2019
Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis FungoidesJohn T O'Malley, Adele de Masson, Elizabeth L Lowry, et al.Nature|November 29, 2019
Global satellite-observed daily vertical migrations of ocean animalsMichael J Behrenfeld, Peter Gaube, Alice Della Penna, et al.The British Journal of Dermatology|September 24, 2020
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension studyM J Cork, D Thaçi, L F Eichenfield, et al.Science Translational Medicine|October 9, 2015
TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCLIlan R Kirsch, Rei Watanabe, John T O'Malley, et al.Nature Medicine|May 4, 2023
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trialsGil Yosipovitch, Nicholas Mollanazar, Sonja Ständer, et al.American Journal of Clinical Dermatology|May 14, 2022
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller, et al.JCI Insight|January 11, 2019
Benign T cells drive clinical skin inflammation in cutaneous T cell lymphomaPablo Vieyra-Garcia, Jack D Crouch, John T O'Malley, et al.The Journal of Allergy and Clinical Immunology. Global|October 2, 2023
Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccinesMichael E Wechsler, Adelmir Souza-Machado, Christine Xu, et al.Pageof 19